#VaccinesWork
Each April, World Immunisation Week gathers people from around the world to highlight the importance of vaccines and how they protect people against various diseases. So, to mark the event, we at TEAMIT Research are taking part to promote the campaign “The Big Catch-up”. These seven days will be a moment to join forces with many others and push for more vaccinations of millions of children, back to pre-pandemic vaccination levels. In today’s post, we speak with Teamit Research Head of Partnerships, Gianmarco Di Mauro. He’ll share his insights and learnings from across two major vaccine-centred projects, in which our spin-off Teamit Institute actively participates.
Gianmarco, thanks for taking some time to answer these questions for our readers. Before we delve into specifics, could you give us a bit of background on who you are and how that has influenced your role in vaccine-related projects across Europe?
I am a molecular biologist by training and have spent the last 5 years managing research initiatives. When I joined Teamit, I had the opportunity to set up and lead a company unit specialised in supporting the generation of scientific evidence to assess safety and efficacy of medicines and vaccines once in the market and used by patients. Thanks to our collaboration with the VAC4EU research network during the COVID-19 pandemic, we participated in several research projects aimed at evaluating the effects of vaccines against the COVID-19 virus. Moreover, in the past two years, Teamit has been participating in an Innovative Medicines Initiative-funded initiative called PROMISE that aims to study and prepare effective treatments against another important infectious disease, the respiratory syncytial virus (RSV).
